Pilot study of topotecan and high-dose cyclophosphamide for resistant pediatric solid tumors
Academic ArticleArticle
Overview
MeSH Major
Bone Neoplasms
Osteosarcoma
abstract
Its antitumor potential and limited toxicity make HD-Cy/Topo an attractive choice for inclusion in aggressive salvage programs aimed at achieving cures of resistant tumors. It may also merit incorporation into frontline treatment protocols.
